Current compounding status As of March 2025, the FDA determined that the tirzepatide shortage is resolved, which impacts compounding eligibility
Some of these adverse effects reported were Toxic Epidermal Necrolysis (a rare but life-threatening skin condition characterized by painful blisters and large areas of skin peeling), air embolism, thyroid dysfunction, and liver, kidney, and neurologic toxicity (The dark side of skin lightening- PubMed) With the proliferation of med-spas in an unregulated fashion, there is a risk of inadequately trained or untrained people giving IV injections in a non-sterile way, which can lead to sepsis and transmission of infections like HIV and hepatitis
To do this, the body must be able to recycle glutathione
Several studies have indicated that the capacity of flavanols and flavones to inhibit the active site is largely dependent on hydrogen bonds between the polyphenol ligand hydroxyl groups and the catalytic residues of the binding site [252]
The peptides are BPC 157, TB 500, and GHK Cu
